The financials
Inhibrx Biosciences, Inc. by the numbers
For the full year FY2025, revenue was $1.3M (+550% year on year) and net income −$140M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | n/a | $0 | n/a |
| Operating income | −$31M | −$43M | n/a |
| Net income | −$33M | −$43M | n/a |
| Diluted EPS | −$2.15 | −$2.80 | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $0.00
License grew -100% year on year
Segment Latestyear on year
- License$0.00$0.00year on year -100%-100%